Overview

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

Phase:

Phase 3

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Seladelpar